This content is from: Premium

This Hedge Fund-Backed Biopharma Company Is Still Trying to Go Public

Zentalis set terms for its offering but warns that Covid-19 could set back many crucial developments for the company.

A fledgling biopharma company with heavy hedge fund backing is seemingly moving forward with its initial public offering, despite the stock market’s sharp selloff and overall volatility and growing concern that the Covid-19 virus is spreading throughout the United States.On Friday Renaissance Capital, an IPO research specialist, said in a

To continue reading, subscribe now to Premium Journalism. Already a subscriber? Login.

Related Content